Candesartan/Metformin

坎地沙坦/二甲双胍

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCandesartan/Metformin
Drug Alias Name坎地沙坦+二甲双胍Candesartan+Metformin二甲双胍/坎地沙坦metformin/candesartan二甲双胍+坎地沙坦 +[7] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsAngiotensin II Receptor Type 1Protein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Metformin HydrochlorideCandesartan Cilexetil
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHanall
China Registration ClassN/A

Develop Information

Active CompaniesHanall
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A